论文部分内容阅读
目的探讨非小细胞肺癌(NSCLC)中CD44V6及NM23/NDPK的表达及其在NSCLC发生、转移以及预后中的意义。方法采用S-P免疫组化染色技术,检测69例NSCLC中CD44V6及NM23/NDPK的表达情况。结果肺癌原发灶CD44V6阳性表达率与NSCLC淋巴结转移及临床分期呈正相关(P<0.05,P<0.01),NM23/NDPK阳性表达率与NSCLC淋巴结转移及临床分期呈负相关(P<0.05),CD44V6及NM23/NDPK的表达与患者的生存率有关(P<0.05),但与组织学分级及分化程度无关。CD44V6及NM23/NDPK在肺癌中的表达呈明显负相关(P<0.01)。结论对NSCLC进行CD44V6及NM23/NDPK的检测,有助于预测NSCLC进展程度和淋巴结转移,以及评估NSCLC患者的预后。
Objective To investigate the expression of CD44V6 and NM23 / NDPK in non-small cell lung cancer (NSCLC) and its significance in the occurrence, metastasis and prognosis of NSCLC. Methods The expression of CD44V6 and NM23 / NDPK in 69 cases of NSCLC were detected by S-P immunohistochemical staining. Results The positive rate of CD44V6 in NSCLC was positively correlated with the lymph node metastasis and clinical stage (P <0.05, P <0.01). The positive expression rate of NM23 / NDPK was negatively correlated with lymph node metastasis and clinical stage in NSCLC (P <0.05) The expression of CD44V6 and NM23 / NDPK correlated with the survival rate of patients (P <0.05), but not with histological grade and degree of differentiation. The expression of CD44V6 and NM23 / NDPK in lung cancer was negatively correlated (P <0.01). Conclusion The detection of CD44V6 and NM23 / NDPK in NSCLC can help predict the progression of NSCLC and lymph node metastasis, as well as assess the prognosis of patients with NSCLC.